probucol has been researched along with Alloxan Diabetes in 59 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We examined the effect of probucol, an antihyperlipidemic drug with potent antioxidant properties, on cataract formation in streptozotocin (STZ)-induced hyperglycemic rats that were given 5% D-glucose as drinking water." | 7.91 | Probucol Slows the Progression of Cataracts in Streptozotocin-Induced Hyperglycemic Rats. ( Higashi, K; Ishii, K; Mori, A; Nakahara, T; Sakamoto, K, 2019) |
| "Probucol treatment improves erectile function by restoring endothelial function and preventing cavernous fibrosis in streptozotocin-induced diabetic rats." | 7.83 | Probucol Improves Erectile Function by Restoring Endothelial Function and Preventing Cavernous Fibrosis in Streptozotocin-induced Diabetic Rats. ( Chen, D; Fu, Q; Li, B; Sun, DQ; Zhang, H; Zhang, KQ, 2016) |
| " However, the underlying mechanisms for the increased propensity for AF in the setting of DM and the potential effects of probucol on atrial remodeling remain unclear." | 7.81 | Probucol prevents atrial remodeling by inhibiting oxidative stress and TNF-α/NF-κB/TGF-β signal transduction pathway in alloxan-induced diabetic rabbits. ( Cheng, L; Fu, H; Li, G; Li, J; Liu, C; Liu, T; Wang, X, 2015) |
| "Probucol, an agent characterized by lipid-lowering and antioxidant property, retards atherosclerosis effectively." | 7.81 | Probucol Protects Against Atherosclerosis Through Lipid-lowering and Suppressing Immune Maturation of CD11c+ Dendritic Cells in STZ-induced Diabetic LDLR-/- Mice. ( Dong, Z; Ge, J; Hu, K; Huang, W; Jin, X; Liu, G; Ma, X; Sun, A; Wang, K; Xu, F; Zhao, J; Zhu, H; Zou, Y, 2015) |
| "We investigated the effects of long-term treatment with probucol, a hypolipidemic agent with antioxidative action, insulin, or their combination on cataracts of streptozotocin-induced diabetic rats fed a high cholesterol diet." | 7.73 | Combined effect of probucol and insulin on cataracts of diabetic rats fed a high cholesterol diet. ( Ito, M; Kimura, H; Kyuki, K; Yoshida, M, 2005) |
| "Probucol was administered by gavage and the contrast diatrizoate (60%) was injected via femoral vein." | 5.51 | Probucol Protects Against Contrast-Induced Acute Kidney Injury via the Extracellular Signal-Regulated Kinases 1 and 2 (ERK1/2)/JNK-Caspase 3 Pathway in Diabetic Rats. ( Chen, J; Jiao, Z; Li, G; Liu, T; Liu, Y; Ma, X; Tse, G; Yuan, R, 2019) |
| "This study was to explore the effect and mechanism of Probucol on STZ-induced erectile dysfunction in diabetic rats." | 4.02 | Probucol improves erectile function by regulating endoplasmic reticulum stress in rats with streptozotocin-induced diabetes. ( Fu, Q; Ruan, Z; Wang, H; Xu, Z; Zang, Z; Zhang, K, 2021) |
| " Therefore, we have tested whether the previously proven blood-brain barrier protective agent, probucol, can prevent blood-brain barrier breakdown and cognitive decline in a dietary-induced murine model of diabetic insulin resistance." | 3.91 | Probucol prevents blood-brain barrier dysfunction and cognitive decline in mice maintained on pro-diabetic diet. ( Al-Salami, H; Brook, E; Fimognari, N; Lam, V; Mamo, JC; Mooranian, A; Nesbit, M; Takechi, R, 2019) |
| "We examined the effect of probucol, an antihyperlipidemic drug with potent antioxidant properties, on cataract formation in streptozotocin (STZ)-induced hyperglycemic rats that were given 5% D-glucose as drinking water." | 3.91 | Probucol Slows the Progression of Cataracts in Streptozotocin-Induced Hyperglycemic Rats. ( Higashi, K; Ishii, K; Mori, A; Nakahara, T; Sakamoto, K, 2019) |
| "Probucol treatment improves erectile function by restoring endothelial function and preventing cavernous fibrosis in streptozotocin-induced diabetic rats." | 3.83 | Probucol Improves Erectile Function by Restoring Endothelial Function and Preventing Cavernous Fibrosis in Streptozotocin-induced Diabetic Rats. ( Chen, D; Fu, Q; Li, B; Sun, DQ; Zhang, H; Zhang, KQ, 2016) |
| " However, the underlying mechanisms for the increased propensity for AF in the setting of DM and the potential effects of probucol on atrial remodeling remain unclear." | 3.81 | Probucol prevents atrial remodeling by inhibiting oxidative stress and TNF-α/NF-κB/TGF-β signal transduction pathway in alloxan-induced diabetic rabbits. ( Cheng, L; Fu, H; Li, G; Li, J; Liu, C; Liu, T; Wang, X, 2015) |
| "Probucol, an agent characterized by lipid-lowering and antioxidant property, retards atherosclerosis effectively." | 3.81 | Probucol Protects Against Atherosclerosis Through Lipid-lowering and Suppressing Immune Maturation of CD11c+ Dendritic Cells in STZ-induced Diabetic LDLR-/- Mice. ( Dong, Z; Ge, J; Hu, K; Huang, W; Jin, X; Liu, G; Ma, X; Sun, A; Wang, K; Xu, F; Zhao, J; Zhu, H; Zou, Y, 2015) |
| "We investigated the effects of long-term treatment with probucol, a hypolipidemic agent with antioxidative action, insulin, or their combination on cataracts of streptozotocin-induced diabetic rats fed a high cholesterol diet." | 3.73 | Combined effect of probucol and insulin on cataracts of diabetic rats fed a high cholesterol diet. ( Ito, M; Kimura, H; Kyuki, K; Yoshida, M, 2005) |
| "Cataract formation occurred after 13 weeks in diabetic animals compared with 17 weeks for those treated with aminoguanidine, and 16 weeks for those treated with probucol (p < 0." | 3.70 | Effects of inhibition of glycation and oxidative stress on the development of cataract and retinal vessel abnormalities in diabetic rats. ( Agardh, C; Agardh, E; Hultberg, B, 2000) |
| "Probucol was administered by gavage and the contrast diatrizoate (60%) was injected via femoral vein." | 1.51 | Probucol Protects Against Contrast-Induced Acute Kidney Injury via the Extracellular Signal-Regulated Kinases 1 and 2 (ERK1/2)/JNK-Caspase 3 Pathway in Diabetic Rats. ( Chen, J; Jiao, Z; Li, G; Liu, T; Liu, Y; Ma, X; Tse, G; Yuan, R, 2019) |
| "Probucol is a cholesterol-lowering drug, while ursodeoxycholic acid is a hydrophilic bile acid." | 1.48 | Pharmacological effects of nanoencapsulation of human-based dosing of probucol on ratio of secondary to primary bile acids in gut, during induction and progression of type 1 diabetes. ( Al-Salami, H; Al-Sallami, H; Arfuso, F; Goločorbin-Kon, S; Kovacevic, B; Mikov, M; Mooranian, A; Takechi, R; Zamani, N, 2018) |
| "Probucol is an antihyperlipidemic drug with potent antioxidant properties." | 1.46 | Probucol prevents the attenuation of β ( Higashi, K; Ishii, K; Mori, A; Nakahara, T; Sakamoto, K; Wakao, S, 2017) |
| "Probucol treatment increased plasma SOD, decreased plasma MDA and improved hypoinsulinaemia in diabetic rats." | 1.37 | Possible role for the thioredoxin system in the protective effects of probucol in the pancreatic islets of diabetic rats. ( Lin, HL; Liu, DF; Liu, JH; Mei, X; Wang, NN, 2011) |
| "Probucol is a lipid-lowering agent with anti-oxidant effects." | 1.35 | Effects of probucol on hepatic tumor necrosis factor-alpha, interleukin-6 and adiponectin receptor-2 expression in diabetic rats. ( Li, Z; Liu, D; Mei, Z; Shen, W; Xu, X; Zhang, X, 2009) |
| "Treatment with probucol (300 mg/kg/day, i." | 1.30 | Acute probucol treatment partially restores vasomotor activity and abnormal lipid metabolism whereas morphological changes are not affected in aorta from long-term STZ-diabetic rats. ( Karasu, C, 1998) |
| "Primaquine treatment did not affect diabetic rats." | 1.29 | Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rats. ( Archibald, V; Cameron, NE; Cotter, MA; Dines, KC; Maxfield, EK, 1994) |
| "Probucol (1%) was ineffective." | 1.29 | Antioxidant MDL 29,311 prevents diabetes in nonobese diabetic and multiple low-dose STZ-injected mice. ( Dillberger, JE; Heineke, EW; Johnson, MB; Robinson, KM, 1993) |
| "Probucol was given to rats made diabetic by streptozotocin." | 1.29 | Effect of probucol on plasma clearance and organ uptake of chylomicrons and VLDLs in normal and diabetic rats. ( Elsegood, CL; Hirano, T; Mamo, JC; Redgrave, TG; Umeda, Y, 1993) |
| "Probucol treatment had no effect on the cardiac performance of the nondiabetic control rats." | 1.28 | Effects of probucol on impaired cardiac performance and lipid metabolism in streptozotocin-induced diabetic rats. ( Kutsumi, Y; Miyabo, S; Nakai, T; Oida, K; Shimada, Y; Tada, H, 1992) |
| "However, recovery from streptozotocin diabetes was induced by subsequent treatment with probucol." | 1.28 | Effect of probucol on recovery from streptozotocin diabetes in rats. ( Horinuki, R; Kazumi, T; Kimura, Y; Maeda, E; Matsuba, K; Matsushita, M; Morita, M; Nagata, K; Tani, T; Yoshino, G, 1992) |
| "Insulin-dependent diabetes mellitus (IDDM) results from an inflammatory process leading to destruction of the insulin-producing beta cells of the pancreas." | 1.27 | Effect of probucol on development of diabetes mellitus in BB rats. ( Borquaye, S; Drash, AL; Lieberman, I; Rudert, WA; Wang, R, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (6.78) | 18.7374 |
| 1990's | 20 (33.90) | 18.2507 |
| 2000's | 14 (23.73) | 29.6817 |
| 2010's | 18 (30.51) | 24.3611 |
| 2020's | 3 (5.08) | 2.80 |
| Authors | Studies |
|---|---|
| Ladopoulou, E | 1 |
| Matralis, AN | 1 |
| Kourounakis, AP | 1 |
| Mooranian, A | 5 |
| Zamani, N | 3 |
| Luna, G | 2 |
| Al-Sallami, H | 2 |
| Mikov, M | 4 |
| Goločorbin-Kon, S | 4 |
| Stojanovic, G | 1 |
| Arfuso, F | 4 |
| Kovacevic, B | 2 |
| Al-Salami, H | 5 |
| Wang, H | 2 |
| Zhang, K | 2 |
| Ruan, Z | 2 |
| Sun, D | 1 |
| Zhang, H | 3 |
| Lin, G | 1 |
| Hu, L | 1 |
| Zhao, S | 1 |
| Fu, Q | 4 |
| Xu, Z | 1 |
| Zang, Z | 1 |
| Mei, X | 2 |
| Zeng, J | 1 |
| Liu, DF | 2 |
| Zhao, Y | 1 |
| Yang, HL | 1 |
| Li, Y | 1 |
| Qiu, P | 1 |
| Tang, MW | 1 |
| Mori, A | 2 |
| Higashi, K | 2 |
| Wakao, S | 1 |
| Sakamoto, K | 2 |
| Ishii, K | 2 |
| Nakahara, T | 2 |
| Mamo, JC | 2 |
| Lam, V | 1 |
| Brook, E | 1 |
| Fimognari, N | 1 |
| Nesbit, M | 1 |
| Takechi, R | 3 |
| Hu, LL | 1 |
| Zhang, KQ | 2 |
| Tian, T | 1 |
| Ma, X | 2 |
| Jiao, Z | 1 |
| Liu, Y | 1 |
| Chen, J | 1 |
| Li, G | 3 |
| Liu, T | 3 |
| Tse, G | 2 |
| Yuan, R | 1 |
| Elnashar, M | 1 |
| Fu, H | 2 |
| Liu, C | 2 |
| Li, J | 2 |
| Wang, X | 1 |
| Cheng, L | 2 |
| Ziolo, MT | 1 |
| Mohler, PJ | 1 |
| Zhu, H | 1 |
| Jin, X | 1 |
| Zhao, J | 2 |
| Dong, Z | 1 |
| Xu, F | 1 |
| Huang, W | 1 |
| Liu, G | 2 |
| Zou, Y | 1 |
| Wang, K | 1 |
| Hu, K | 1 |
| Sun, A | 1 |
| Ge, J | 1 |
| Negrulj, R | 1 |
| Chen-Tan, N | 1 |
| Al-Sallami, HS | 1 |
| Fakhoury, M | 1 |
| Watts, GF | 1 |
| Ji, W | 1 |
| Huang, J | 1 |
| Liu, L | 1 |
| Wang, Y | 1 |
| Chen, D | 1 |
| Sun, DQ | 1 |
| Li, B | 1 |
| Yang, W | 1 |
| Zhang, X | 1 |
| Li, Z | 1 |
| Liu, D | 1 |
| Xu, X | 1 |
| Shen, W | 1 |
| Mei, Z | 1 |
| Liu, JH | 1 |
| Wang, NN | 1 |
| Lin, HL | 1 |
| Duan, SB | 1 |
| Liu, GL | 1 |
| Wang, YH | 1 |
| Zhang, JJ | 1 |
| Horiuchi, K | 2 |
| Takatori, A | 2 |
| Inenaga, T | 2 |
| Ohta, E | 2 |
| Yamanouchi, J | 1 |
| Kawamura, S | 1 |
| Ishii, Y | 2 |
| Kyuwa, S | 2 |
| Yoshikawa, Y | 2 |
| Itagaki, S | 1 |
| Zanardo, RC | 1 |
| Cruz, JW | 1 |
| Martinez, LL | 1 |
| de Oliveira, MA | 1 |
| Fortes, ZB | 1 |
| Lankin, VZ | 2 |
| Korchin, VI | 2 |
| Konovalova, GG | 2 |
| Lisina, MO | 1 |
| Tikhaze, AK | 1 |
| Akmaev, IG | 1 |
| Yoshida, M | 3 |
| Kimura, H | 2 |
| Kyuki, K | 2 |
| Ito, M | 2 |
| Yen, HW | 1 |
| Lee, HC | 1 |
| Lai, WT | 1 |
| Sheu, SH | 1 |
| Karasu, C | 2 |
| Dewhurst, M | 1 |
| Stevens, EJ | 1 |
| Tomlinson, DR | 1 |
| Soulis-Liparota, T | 1 |
| Cooper, ME | 1 |
| Dunlop, M | 1 |
| Jerums, G | 1 |
| Cameron, NE | 1 |
| Cotter, MA | 1 |
| Archibald, V | 1 |
| Dines, KC | 1 |
| Maxfield, EK | 1 |
| Heineke, EW | 2 |
| Johnson, MB | 2 |
| Dillberger, JE | 1 |
| Robinson, KM | 2 |
| Rhinehart, BL | 1 |
| Sheetz, MJ | 1 |
| Barnhart, RL | 1 |
| Elsegood, CL | 1 |
| Umeda, Y | 1 |
| Hirano, T | 1 |
| Redgrave, TG | 1 |
| Wautier, JL | 2 |
| Zoukourian, C | 1 |
| Chappey, O | 1 |
| Wautier, MP | 1 |
| Guillausseau, PJ | 1 |
| Cao, R | 1 |
| Hori, O | 1 |
| Stern, D | 1 |
| Schmidt, AM | 2 |
| Matsui, H | 1 |
| Okumura, K | 1 |
| Mukawa, H | 1 |
| Hibino, M | 1 |
| Toki, Y | 1 |
| Ito, T | 1 |
| Palmer, AM | 1 |
| Gopaul, N | 1 |
| Dhir, S | 1 |
| Thomas, CR | 1 |
| Poston, L | 1 |
| Tribe, RM | 1 |
| Nishio, Y | 1 |
| Kashiwagi, A | 1 |
| Taki, H | 1 |
| Shinozaki, K | 1 |
| Maeno, Y | 1 |
| Kojima, H | 1 |
| Maegawa, H | 1 |
| Haneda, M | 1 |
| Hidaka, H | 1 |
| Yasuda, H | 1 |
| Horiike, K | 1 |
| Kikkawa, R | 1 |
| Bonnardel-Phu, E | 2 |
| Avila, C | 1 |
| Vicaut, E | 2 |
| Shi, A | 1 |
| Yoshinari, M | 1 |
| Iino, K | 1 |
| Wakisaka, M | 1 |
| Iwase, M | 1 |
| Fujishima, M | 1 |
| El-Swefy, S | 1 |
| Schaefer, EJ | 1 |
| Seman, LJ | 1 |
| van Dongen, D | 1 |
| Sevanian, A | 1 |
| Smith, DE | 1 |
| Ordovas, JM | 1 |
| El-Sweidy, M | 1 |
| Meydani, M | 1 |
| Agardh, E | 2 |
| Hultberg, B | 1 |
| Agardh, C | 1 |
| Kim, SS | 1 |
| Gallaher, DD | 1 |
| Csallany, AS | 1 |
| Park, KS | 1 |
| Kim, JH | 1 |
| Kim, MS | 1 |
| Kim, JM | 1 |
| Kim, SK | 1 |
| Choi, JY | 1 |
| Chung, MH | 1 |
| Han, B | 1 |
| Kim, SY | 1 |
| Lee, HK | 1 |
| Bruun, A | 1 |
| Agardh, CD | 1 |
| Tada, H | 1 |
| Oida, K | 1 |
| Kutsumi, Y | 1 |
| Shimada, Y | 1 |
| Nakai, T | 1 |
| Miyabo, S | 1 |
| Iarkova, RD | 1 |
| Smirnov, LD | 1 |
| Kukharchuk, VV | 1 |
| Tesfamariam, B | 1 |
| Cohen, RA | 1 |
| Yoshino, G | 3 |
| Matsushita, M | 3 |
| Maeda, E | 2 |
| Morita, M | 3 |
| Nagata, K | 2 |
| Matsuba, K | 3 |
| Tani, T | 2 |
| Horinuki, R | 2 |
| Kimura, Y | 2 |
| Kazumi, T | 3 |
| Shimizu, H | 2 |
| Uehara, Y | 2 |
| Shimomura, Y | 2 |
| Tanaka, Y | 1 |
| Kobayashi, I | 2 |
| Sato, N | 1 |
| Mori, M | 1 |
| Morel, DW | 2 |
| Chisolm, GM | 2 |
| Iwai, M | 1 |
| Iwatani, I | 1 |
| Baba, S | 1 |
| Drash, AL | 1 |
| Rudert, WA | 1 |
| Borquaye, S | 1 |
| Wang, R | 1 |
| Lieberman, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2) Randomised, Double-blind,Placebo-controlled Multicentre Trial With 4 Parallel Groups[NCT00328601] | Phase 3 | 170 participants | Interventional | 2005-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
59 other studies available for probucol and Alloxan Diabetes
| Article | Year |
|---|---|
New multifunctional Di-tert-butylphenoloctahydro(pyrido/benz)oxazine derivatives with antioxidant, antihyperlipidemic, and antidiabetic action.
Topics: Animals; Antioxidants; Atherosclerosis; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mel | 2013 |
Bile acid-polymer-probucol microparticles: protective effect on pancreatic β-cells and decrease in type 1 diabetes development in a murine model.
Topics: Animals; Anti-Inflammatory Agents; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Drug | 2019 |
Probucol enhances the therapeutic efficiency of mesenchymal stem cells in the treatment of erectile dysfunction in diabetic rats by prolonging their survival time via Nrf2 pathway.
Topics: Animals; Diabetes Mellitus, Experimental; Erectile Dysfunction; Humans; Hydrogen Peroxide; Male; Mes | 2020 |
Probucol improves erectile function by regulating endoplasmic reticulum stress in rats with streptozotocin-induced diabetes.
Topics: Animals; Diabetes Mellitus, Experimental; Endoplasmic Reticulum Stress; Erectile Dysfunction; Humans | 2021 |
Abnormalities of the PRMT1-ADMA-DDAH1 metabolism axis and probucol treatment in diabetic patients and diabetic rats.
Topics: Amidohydrolases; Animals; Arginine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Huma | 2021 |
Probucol prevents the attenuation of β
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Anticholesteremic Agents; Arterioles; Blood | 2017 |
Probucol prevents blood-brain barrier dysfunction and cognitive decline in mice maintained on pro-diabetic diet.
Topics: Animals; Anti-Inflammatory Agents; Behavior, Animal; Blood-Brain Barrier; Cerebral Cortex; Cognition | 2019 |
Pharmacological effects of nanoencapsulation of human-based dosing of probucol on ratio of secondary to primary bile acids in gut, during induction and progression of type 1 diabetes.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Humans; Insulin-Secreting Cells | 2018 |
Probucol improves erectile function via Activation of Nrf2 and coordinates the HO-1 / DDAH / PPAR-γ/ eNOS pathways in streptozotocin-induced diabetic rats.
Topics: Amidohydrolases; Animals; Arginine; Blood Glucose; Body Weight; Cyclic GMP; Diabetes Mellitus, Exper | 2018 |
Probucol Slows the Progression of Cataracts in Streptozotocin-Induced Hyperglycemic Rats.
Topics: Animals; Antioxidants; Biomarkers; Blood Glucose; Cataract; Diabetes Mellitus, Experimental; Disease | 2019 |
Probucol Protects Against Contrast-Induced Acute Kidney Injury via the Extracellular Signal-Regulated Kinases 1 and 2 (ERK1/2)/JNK-Caspase 3 Pathway in Diabetic Rats.
Topics: Acute Kidney Injury; Animals; Antioxidants; Apoptosis; Caspase 3; Contrast Media; Diabetes Mellitus, | 2019 |
An in vivo pharmacological study: Variation in tissue-accumulation for the drug probucol as the result of targeted microtechnology and matrix-acrylic acid optimization and stabilization techniques.
Topics: Administration, Oral; Animals; Capsules; Cardiotoxicity; Diabetes Mellitus, Experimental; Diabetes M | 2019 |
Probucol prevents atrial remodeling by inhibiting oxidative stress and TNF-α/NF-κB/TGF-β signal transduction pathway in alloxan-induced diabetic rabbits.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Atrial Fibrillation; Atrial Remodeling; Biomarkers; | 2015 |
Defining the role of oxidative stress in atrial fibrillation and diabetes.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Atrial Fibrillation; Atrial Remodeling; Diabetes Me | 2015 |
Probucol Protects Against Atherosclerosis Through Lipid-lowering and Suppressing Immune Maturation of CD11c+ Dendritic Cells in STZ-induced Diabetic LDLR-/- Mice.
Topics: Animals; Aortic Diseases; Atherosclerosis; Biomarkers; CD11c Antigen; Cells, Cultured; Cholesterol; | 2015 |
Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes.
Topics: Administration, Oral; Animals; Capsules; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Probu | 2016 |
4-HNE expression in diabetic rat kidneys and the protective effects of probucol.
Topics: Aldehydes; Animals; Antioxidants; Biomarkers; Blotting, Western; Diabetes Mellitus, Experimental; Di | 2016 |
Probucol Improves Erectile Function by Restoring Endothelial Function and Preventing Cavernous Fibrosis in Streptozotocin-induced Diabetic Rats.
Topics: Animals; Anticholesteremic Agents; Diabetes Mellitus, Experimental; Endothelium; Erectile Dysfunctio | 2016 |
Probucol prevents atrial ion channel remodeling in an alloxan-induced diabetes rabbit model.
Topics: Action Potentials; Alloxan; Animals; Anti-Arrhythmia Agents; Antioxidants; Atrial Fibrillation; Atri | 2016 |
Effects of probucol on hepatic tumor necrosis factor-alpha, interleukin-6 and adiponectin receptor-2 expression in diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Enzyme-Linked Immunosorbent Assay; Fatty Liver; Interleuki | 2009 |
Possible role for the thioredoxin system in the protective effects of probucol in the pancreatic islets of diabetic rats.
Topics: Animals; Antioxidants; Blood Glucose; Body Weight; Carrier Proteins; Cell Cycle Proteins; Control Gr | 2011 |
Epithelial-to-mesenchymal transdifferentiation of renal tubular epithelial cell mediated by oxidative stress and intervention effect of probucol in diabetic nephropathy rats.
Topics: Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Epithelial-Mesenchym | 2012 |
The effect of probucol on atherosclerosis in streptozotocin-induced diabetic-hyperlipidemic APA hamsters in different stages of atherosclerosis.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Aorta; Arteriosclerosis; Cholesterol; Cricetinae; D | 2002 |
Protective effects of probucol treatment on pancreatic beta-cell function of SZ-induced diabetic APA hamsters.
Topics: Aldehydes; Animals; Anticholesteremic Agents; Antioxidants; Biomarkers; Cricetinae; Diabetes Mellitu | 2003 |
Probucol restores the defective leukocyte-endothelial interaction in experimental diabetes.
Topics: Animals; Antioxidants; Blood Circulation; Blood Glucose; Cell Migration Inhibition; Diabetes Mellitu | 2003 |
Role of antioxidant enzymes and antioxidant compound probucol in antiradical protection of pancreatic beta-cells during alloxan-induced diabetes.
Topics: Animals; Antioxidants; Diabetes Mellitus, Experimental; Glutathione Peroxidase; Glutathione Transfer | 2004 |
Combined effect of probucol and insulin on cataracts of diabetic rats fed a high cholesterol diet.
Topics: Animals; Blood Glucose; Body Weight; Cataract; Cholesterol; Cholesterol, Dietary; Diabetes Mellitus, | 2005 |
Combined effect of probucol and insulin on renal damage in diabetic rats fed a high cholesterol diet.
Topics: Albuminuria; Animals; Anticholesteremic Agents; Antioxidants; Blood Glucose; Cholesterol; Cholestero | 2006 |
Effects of acetylcysteine and probucol on contrast medium-induced depression of intrinsic renal glutathione peroxidase activity in diabetic rats.
Topics: Acetylcysteine; Animals; Antioxidants; Contrast Media; Diabetes Mellitus, Experimental; Diatrizoate | 2007 |
Effects of anti-oxidant treatment on sciatic nerve dysfunction in streptozotocin-diabetic rats; comparison with essential fatty acids.
Topics: Animals; Antioxidants; Cholesterol; Diabetes Mellitus, Experimental; Fatty Acids, Essential; gamma-L | 1995 |
The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat.
Topics: Albuminuria; Aldehyde Reductase; Animals; Antioxidants; Blood Glucose; Body Weight; Butylated Hydrox | 1995 |
Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Inositol; Male; Motor Neurons; | 1994 |
Antioxidant MDL 29,311 prevents diabetes in nonobese diabetic and multiple low-dose STZ-injected mice.
Topics: Aging; Animals; Antioxidants; Atrophy; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mell | 1993 |
MDL 29311. Antioxidant with marked lipid- and glucose-lowering activity in diabetic rats and mice.
Topics: Animals; Diabetes Mellitus, Experimental; Fasting; Fatty Acids, Nonesterified; Female; Hypoglycemic | 1993 |
Effect of probucol on plasma clearance and organ uptake of chylomicrons and VLDLs in normal and diabetic rats.
Topics: Animals; Chylomicrons; Diabetes Mellitus, Experimental; Lipoproteins, VLDL; Male; Metabolic Clearanc | 1993 |
Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats.
Topics: Adult; Albumins; Animals; Antioxidants; Capillary Permeability; Cattle; Cells, Cultured; Diabetes Me | 1996 |
Increased oxysterol contents in diabetic rat hearts: their involvement in diabetic cardiomyopathy.
Topics: Animals; Anticholesteremic Agents; Cardiomyopathies; Diabetes Mellitus, Experimental; Hydroxycholest | 1997 |
Endothelial dysfunction in streptozotocin-diabetic rats is not reversed by dietary probucol or simvastatin supplementation.
Topics: Animals; Antioxidants; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diet; Dinoprost; | 1998 |
Altered activities of transcription factors and their related gene expression in cardiac tissues of diabetic rats.
Topics: Animals; Antioxidants; Diabetes Mellitus, Experimental; Gene Expression; Heart; Heme Oxygenase (Decy | 1998 |
Acute probucol treatment partially restores vasomotor activity and abnormal lipid metabolism whereas morphological changes are not affected in aorta from long-term STZ-diabetic rats.
Topics: Animals; Anticholesteremic Agents; Aorta; Cholesterol; Diabetes Mellitus, Experimental; Endothelium, | 1998 |
Acute modulation of albumin microvascular leakage by advanced glycation end products in microcirculation of diabetic rats in vivo.
Topics: Albumins; Animals; Anticholesteremic Agents; Blood Glucose; Capillary Leak Syndrome; Diabetes Mellit | 1999 |
Lysophosphatidylcholine molecular species in low density lipoprotein and high density lipoprotein in alloxan-induced diabetic rats: effect of probucol.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Hyp | 1999 |
The effect of vitamin E, probucol, and lovastatin on oxidative status and aortic fatty lesions in hyperlipidemic-diabetic hamsters.
Topics: Animals; Animals, Newborn; Anticholesteremic Agents; Antioxidants; Arteriosclerosis; Cells, Cultured | 2000 |
[Role of oxidative stress in permeability changes observed in the microcirculation of diabetic rats in vivo].
Topics: Animals; Capillary Permeability; Catalase; Diabetes Mellitus, Experimental; Diabetic Angiopathies; D | 2000 |
Effects of inhibition of glycation and oxidative stress on the development of cataract and retinal vessel abnormalities in diabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Cataract; Cysteine; Diabetes Mellitus, Experimental; Diabetic R | 2000 |
Vitamin E and probucol reduce urinary lipophilic aldehydes and renal enlargement in streptozotocin-induced diabetic rats.
Topics: Aldehydes; Animals; Antioxidants; Ascorbic Acid; Blood Glucose; Diabetes Mellitus, Experimental; Dia | 2000 |
Effects of insulin and antioxidant on plasma 8-hydroxyguanine and tissue 8-hydroxydeoxyguanosine in streptozotocin-induced diabetic rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antioxidants; Biomarkers; Blood Glucose; Deoxyguanosine; Diabe | 2001 |
Retinal glial cell immunoreactivity and neuronal cell changes in rats with STZ-induced diabetes.
Topics: Animals; Antioxidants; Calbindins; Carrier Proteins; Cell Count; cis-trans-Isomerases; Diabetes Mell | 2001 |
Effects of probucol on impaired cardiac performance and lipid metabolism in streptozotocin-induced diabetic rats.
Topics: Animals; Biological Transport, Active; Blood Glucose; Body Weight; Calcium; Cardiac Output; Chromato | 1992 |
[Antioxidant probucol prevents development of alloxan diabetes and decrease of antioxidant enzyme activity in rat tissues].
Topics: Animals; Diabetes Mellitus, Experimental; Glutathione Peroxidase; Insulin; Islets of Langerhans; Liv | 1992 |
Free radicals mediate endothelial cell dysfunction caused by elevated glucose.
Topics: Animals; Aorta; Blood Glucose; Diabetes Mellitus, Experimental; Endothelium, Vascular; Free Radical | 1992 |
Effect of probucol on recovery from streptozotocin diabetes in rats.
Topics: Animals; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Fatty Acids, Nonesterified; Ma | 1992 |
Probucol attenuated hyperglycemia in multiple low-dose streptozotocin-induced diabetic mice.
Topics: Administration, Oral; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Flow Cytometry; Gluco | 1991 |
Probucol partially prevents development of diabetes in NOD mice.
Topics: Aging; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diet; Female; Flow Cytometry; Glycos | 1991 |
Effect of probucol on triglyceride turnover in streptozotocin-diabetic rats.
Topics: Animals; Cholesterol; Diabetes Mellitus, Experimental; Lipoproteins, VLDL; Male; Phospholipids; Prob | 1991 |
Antioxidant treatment of diabetic rats inhibits lipoprotein oxidation and cytotoxicity.
Topics: Animals; Antioxidants; Blood Glucose; Body Weight; Cell Survival; Cells, Cultured; Diabetes Mellitus | 1989 |
Protective effect of probucol on alloxan diabetes in rats.
Topics: Alloxan; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Glycosuria; Islets of | 1989 |
Lipoprotein oxidation and cytotoxicity: effect of probucol on streptozotocin-treated rats.
Topics: Animals; Cell Cycle; Cell Survival; Cells, Cultured; Diabetes Mellitus, Experimental; Drug Evaluatio | 1988 |
Effect of probucol on development of diabetes mellitus in BB rats.
Topics: Actuarial Analysis; Age Factors; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1 | 1988 |